Skip to main content
Site Search
Investors Home
News Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
SEC Filings
All Filings
Quarterly Results
Annual Reports & Proxies
Analyst Coverage
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
RSS Feeds
News Releases
Investors Home
News Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
SEC Filings
All Filings
Quarterly Results
Annual Reports & Proxies
Analyst Coverage
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
RSS Feeds
Normal
Get News Alerts by RSS
(opens in new window)
Press release year list
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
12/11/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12/11/2020
Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS
12/09/2020
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
12/09/2020
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020
12/02/2020
Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted
11/17/2020
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
11/06/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11/05/2020
Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer
11/05/2020
Puma Biotechnology Reports Third Quarter 2020 Financial Results
11/03/2020
Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference
10/22/2020
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
10/15/2020
NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers
10/05/2020
Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer
10/02/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09/08/2020
Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
09/03/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
08/19/2020
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
08/10/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
08/06/2020
Puma Biotechnology Reports Second Quarter 2020 Financial Results
07/27/2020
Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers
07/23/2020
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
07/16/2020
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
07/09/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06/02/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05/08/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05/07/2020
Puma Biotechnology Reports First Quarter 2020 Financial Results
05/07/2020
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
05/06/2020
Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020
04/30/2020
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
04/23/2020
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
04/03/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/25/2020
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
03/05/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/28/2020
Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
02/26/2020
Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
02/20/2020
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
02/07/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/05/2020
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results
01/13/2020
Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
01/09/2020
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/07/2020
Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference